November 18, 2026
Health news, explained with evidence
LIVE

Experimental mRNA Nasal Drops Boost Memory and Prevent Cognitive Decline in Mice

🔬 Research 2 min read 👁 5

University of Sydney researchers developed experimental nasal drops utilizing mRNA technology that successfully enhanced memory in aged mice and protected an Alzheimer's disease mouse model from cognitive decline.

Experimental mRNA Nasal Drops Boost Memory and Prevent Cognitive Decline in Mice🔬Research

Photo: Medical Xpress

Key points

  • Experimental nasal drops use mRNA technology to boost brain-derived neurotrophic factor.
  • The noninvasive treatment successfully bypassed the blood-brain barrier in mice.
  • Memory improved in aged mice and was protected in an Alzheimer's model without clearing amyloid plaques.

Scientists at the University of Sydney have created an experimental nasal spray that improves learning and memory in older mice while preventing memory deterioration in a mouse model of Alzheimer's disease. Led by Professor Greg Neely at the Charles Perkins Center, the study utilized messenger RNA technology packaged within lipid nanoparticles—a delivery system similar to that used in COVID-19 vaccines. Published in Advanced Science, the study was inspired by the science fiction story "Flowers for Algernon."

The nasal treatment delivers mRNA instructions designed to prompt the nasal passages to produce brain-derived neurotrophic factor (BDNF), a natural protein vital for neuron survival, plasticity, and memory formation. Because BDNF levels typically decline with age and in neurodegenerative conditions, researchers administered the treatment twice weekly to aged mice and a rapid-onset Alzheimer's model. Treated aged mice performed comparably to young mice in standard behavioral tests, while the Alzheimer's model mice were protected against expected severe cognitive decline.

Notably, the therapy preserved brain function without clearing amyloid plaques, which are protein clumps classically associated with Alzheimer's. This suggests that raising BDNF levels may help support neuron health independently of plaque clearance. However, readers should note that these findings are currently limited to preclinical animal models, and researchers emphasize that human clinical trials are required to test safety and efficacy. Always consult a qualified healthcare provider for personal medical decisions.

What to know:

  • Researchers developed noninvasive nasal drops using mRNA technology to deliver brain-supporting proteins directly to the central nervous system.
  • The treatment restored cognitive function in aged mice and prevented memory loss in an Alzheimer's mouse model without reducing amyloid plaques.
  • The approach successfully bypassed the blood-brain barrier in preclinical tests, though human clinical trials are still needed.

Source Medical Xpress — medicalxpress.com/news/2026-11-algernon-experimental-nose-memory-mice.h… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.